Lymphoma

Top Story

Brentuximab vedotin plus gemcitabine safe, active for young patients with Hodgkin lymphoma

Brentuximab vedotin plus gemcitabine safe, active for young patients with Hodgkin lymphoma
September 21, 2018

UK panel rejects Kymriah for adults with lymphoma due to cost

September 19, 2018
An independent body that offers guidance to improve health and social care in England recommended against the use of tisagenlecleucel, a chimeric antigen receptor T-cell…
In the Journals Plus

Brentuximab vedotin data ‘practice changing’ for older patients with Hodgkin lymphoma

September 18, 2018
Brentuximab vedotin administered sequentially before and after standard chemotherapy appeared effective and safe for older patients with previously untreated Hodgkin…

7 updates for Childhood Cancer Awareness Month

September 14, 2018
September is Childhood Cancer Awareness Month, a campaign to spotlight the types of cancer that largely affect children, draw attention to survivorship issues, and raise…
More Headlines »
CME ABIM MOC

Ace the Case: A 72-Year-Old, Healthy, and Asymptomatic Woman With Incidentally Diagnosed Leukemia

There is no commercial support for this activity.

This educational activity will discuss the management of a 72-year old, asymptomatic female with severe leukopenia…
More »
Video
Meeting News

VIDEO: CAR T cells effective for non-Hodgkin lymphoma

March 13, 2018
More »
Resource Centers
Immuno-Oncology Resource Center

Immuno-Oncology Resource Center

CME

Multimodality Treatment Strategies for NSCLC: A Symposium at the US Oncology Annual Meeting

This activity is supported by an educational grant from Merck & Co., Inc.

Lung cancer is a leading cause of cancer death worldwide. Approximately 85% of diagnosed lung cancers are non-small…
More »